Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.55 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.55 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.55 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | PIK3C3 | Q8NEB9 | 7/20 | 0.44 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16130585 | 1.00 | CHRNB2 (0.55) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL16130557 | 1.00 | CHRNB2 (0.55) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| Bromide SCHEMBL5224743 | 0.98 | CHRNB2 (0.53) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL2606078 | 0.82 | ATR (0.40) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL27367885 | 0.82 | ATR (0.40) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL30433564 | 0.82 | MDM2 (0.39) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL13634754 | 0.82 | CCNC (0.42) | CHRNA7TSHR | |
| SCHEMBL24465524 | 0.82 | MAOB (0.43) | HTR1A | |
| SCHEMBL22425352 | 0.82 | MAOB (0.43) | HTR1A | |
| SCHEMBL22425355 | 0.82 | MAOB (0.43) | HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361280-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
| WO-2024081363-A1 | COMPOSITION COMPRISING A FIRST RAS INHIBITOR, SECOND RAS INHIBITOR AND A SHP2 INHIBITOR FOR USE IN THE TREATMENT OF CANCER | Revolution Medicines, Inc. (US) | 2024-04-18 | — | — | WO | disclosed |
| EP-3380469-B1 | BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| US-11028079-B2 | Small molecule BET bromodomain inhibitors and uses thereof | CONVERGENE, LLC (US) | 2021-06-08 | — | — | US | disclosed |
| EP-3322706-B1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2020-11-11 | — | — | EP | disclosed |
| US-20200223836-A1 | SMALL MOLECULE BET BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE LLC | 2020-07-16 | — | — | US | disclosed |
| EP-3416957-B1 | 6-HETEROCYCLYL-4-MORPHOLIN-4-YLPYRIDIN-2-ONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | SPRINT BIOSCIENCE AB (SE) | 2020-07-01 | — | — | EP | disclosed |
| US-20190127374-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2019-05-02 | — | — | US | disclosed |
| EP-3052504-B1 | CONFORMATIONALLY RESTRICTED PI3K AND MTOR INHIBITORS | UNIV BASEL (CH) | 2019-02-06 | — | — | EP | disclosed |
| US-10174027-B2 | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-7652020-B2 | novel hydantoin derivatives to inhibit matrix metalloproteinases (MMPs), a disintegrin and metalloproteases (ADAMs) and/or tumor necrosis factor alpha converting enzyme (TACE) and in so doing prevent the release of tumor necrosis factor alpha (TNF- alpha ); autoimmune diseases; side effect reduction | SCHERING CORPORATION (US) | 2010-01-26 | — | — | US | disclosed |
| WO-2009112845-A1 | AMIDO-THIOPHENE COMPOUNDS AND THEIR USE | THE UNIVERSITY OF EDINBURGH (GB) | 2009-09-17 | — | — | WO | disclosed |
| WO-2007064749-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS AND MICROBIAL DISEASES | SCHERING CORPORATION (US) | 2007-06-07 | — | — | WO | disclosed |
| EP-1660065-A2 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-05-31 | — | — | EP | disclosed |
| EP-1660064-A2 | TREATMENT OF LEARNING DISABILITIES AND MOTOR SKILLS DISORDER WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005102330-A2 | AMINO METHYLATED 2-PYRIDINONES | WASHINGTION UNIVERSITY (US) | 2005-11-03 | — | — | WO | disclosed |
| EP-1534291-A2 | 2-(PHENOXYMETHYL)- AND 2-(PHENYLTHIOMETHYL)- MORPHOLINE DERIVATIVES FOR USE AS SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2005020976-A2 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005020975-A2 | TREATMENT OF LEARNING DISABILITIES AND MOTOR SKILLS DISORDER WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2004017977-A2 | 2- (PHENOXYMETHYL)- AND 2- (PHENYLTHIOMETHYL)-MORPHOLINE DERIVATIVES FOR USE AS SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10174027-B2 | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | CHRNB2 2323/4885CHRNB4 1625/4885CHRNA3 1738/4885 |
| US-20250361280-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | CHRNB2 4820/4885CHRNB4 4831/4885CHRNA3 4860/4885 |
| US-11028079-B2 | Small molecule BET bromodomain inhibitors and uses thereof | BRDT, BRD4, BRD3 | CHRNB2 1994/4885CHRNB4 2313/4885CHRNA3 2085/4885 |
| US-20190127374-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | CHRNB2 2323/4885CHRNB4 1625/4885CHRNA3 1738/4885 |
| US-20200223836-A1 | SMALL MOLECULE BET BROMODOMAIN INHIBITORS AND USES THEREOF | BRDT, BRD4, BRD3 | CHRNB2 1994/4885CHRNB4 2313/4885CHRNA3 2085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.